📰 Continuous Commitment News
Continuous Commitment News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Continuous Commitment. Real-time updates on events, politics, business and more.
May 16, 2024
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541)...
May 16, 2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the...
February 23, 2024
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...
November 9, 2023
REEDLEY, Calif. (KGPE/KSEE) – Reedley’s Adventist Health has achieved a five-star rating for specialty care, according to new research released by Healthgrades. Based on the 2024 Healthgrades analysis at approximately 4,500 hospitals nationwide, Adventist Health Reedley received a five-star rating for the treatment of Pneumonia Medallion. “We are honored to receive this recognition from Healthgrades […]
July 25, 2023
Otis (NYSE: OTIS), the world's leading company for elevator and escalator manufacturing, installation, and service, recently unveiled its newly transformed office space in Malaysia. The project is part of Otis' global initiative to redesign how and where colleagues work enabling more collaborations, strengthening community connections, and fueling innovation. It also demonstrates Otis' continuous commitment to reduce the environmental impact from its operations while improving bus...
April 25, 2023
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 -amyotrophic lateral sclerosis is a devastating, uniformly... | April 25, 2023
April 25, 2023
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly
December 5, 2022
SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. ... | December 5, 2022
October 17, 2022
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration
July 26, 2022
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf approved, tofersen would be